Clinical Trials Logo

Clinical Trial Summary

The objective of this study was to evaluate the plasma amphetamine concentration/time profile of amphetamine extended release oral suspension in children aged 4 to 5 years with attention-deficit/hyperactivity disorder, following a single 2.5 mg dose of amphetamine extended release oral suspension.


Clinical Trial Description

DYANAVEL® XR is an extended-release oral suspension that contains 2.5 mg/mL amphetamine base (amphetamine extended-release oral suspension; AMPH EROS). Drug-resin complexation is formed with the amphetamine and sodium polystyrene sulfonate, an ion exchange resin. The extended release feature of the product is achieved by coating a portion of the drug/resin complexes with an extended release coating. AMPH EROS contains approximately a 3.2:1 ratio of d-amphetamine compared to l-amphetamine.

The objective of this study was to evaluate the plasma amphetamine concentration/time profile of AMPH EROS in children aged 4 to 5 years with attention-deficit/hyperactivity disorder, following a single 2.5 mg dose of AMPH EROS.

These data will guide appropriate dosing in planned safety and efficacy studies with AMPH EROS in a preschool population with attention-deficit/hyperactivity disorder. ;


Study Design


Related Conditions & MeSH terms

  • Attention Deficit Disorder with Hyperactivity
  • Attention Deficit Hyperactivity Disorder
  • Hyperkinesis

NCT number NCT03610464
Study type Interventional
Source Tris Pharma, Inc.
Contact
Status Completed
Phase Phase 4
Start date May 7, 2018
Completion date May 23, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT06129396 - Effects of Aerobic Exercise Intervention in Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD) N/A
Completed NCT04779333 - Lifestyle Enhancement for ADHD Program 2 N/A
Recruiting NCT05935722 - Evaluation of a Home-based Parenting Support Program: Parenting Young Children N/A
Completed NCT03148782 - Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase N/A
Completed NCT04832737 - Strength-based Treatment Approach for Adults With ADHD N/A
Recruiting NCT04631042 - Developing Brain, Impulsivity and Compulsivity
Recruiting NCT05048043 - Development of a Game-supported Intervention N/A
Completed NCT03337646 - Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism Phase 4
Not yet recruiting NCT06080373 - Formulation-based CBT for Adult Inmates With ADHD: A Randomized Controlled Trial N/A
Not yet recruiting NCT06454604 - Virtual Reality Treatment for Emerging Adults With ADHD Phase 2
Not yet recruiting NCT06406309 - Settling Down for Sleep in ADHD: The Impact of Sensory and Arousal Systems on Sleep in ADHD N/A
Completed NCT02911194 - a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD) N/A
Completed NCT02477280 - Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance Phase 4
Completed NCT02390791 - New Technologies to Help Manage ADHD N/A
Completed NCT02555150 - A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD Phase 3
Completed NCT02829970 - Helping College Students With ADHD Lead Healthier Lifestyles N/A
Completed NCT02780102 - Cognitive-Motor Rehabilitation, Stimulant Drugs, and Active Control in the Treatment of ADHD N/A
Completed NCT02473185 - Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the QbTest Phase 4
Recruiting NCT04296604 - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations N/A
Recruiting NCT04175028 - Neuromodulation of Executive Function in the ADHD Brain N/A